Previous 10 | Next 10 |
- Celgene licenses JTX-8064, resulting in $50.0 million upfront payment to Jounce - - Jounce retains full worldwide rights to vopratelimab, JTX‑4014 and all discovery programs - - Company to host conference call and webcast today at 5:00 p.m. ET - CAMBRIDGE, Mass., July ...
- Commenced patient enrollment in Phase 2 clinical trial of vopratelimab in combination with ipilimumab - - Preliminary efficacy and relationship to biomarker data expected in 2020 - CAMBRIDGE, Mass., June 18, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a cli...
Nothing strengthens authority so much as silence. " - Leonardo da Vinci Today, we look at a small, early-stage development firm trying to use the body's immune system to attack tumors. Company Overview: Jounce Therapeutics ( JNCE ) IPO'd in 2017 and is a Massachusetts-based clinical...
CAMBRIDGE, Mass., June 11, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will present at two upcoming inve...
Jounce Therapeutics, Inc. (JNCE) Q1 2019 Results Earnings Conference Call May 08, 2019 08:00 AM ET Company Participants Komal Joshi - Investor Relations Dr. Rich Murray - President and Chief Executive Officer Dr. Beth Trehu - Chief Medical Officer Kim Drapkin - Chief Financial ...
Peloton Therapeutics, Inc. ( PLTX ) is at an advanced stage of development, which will please many investors. The company expects to start patient enrollment for its Phase 3 clinical trial in the second half of 2019. Additionally, three years ago, competitors were valued at $250-500 million in...
Jounce Therapeutics ( JNCE ) Q1 results : Revenues: $11M (-1.8%). More news on: Jounce Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
Jounce Therapeutics (NASDAQ: JNCE ): Q1 GAAP EPS of -$0.38 misses by $0.12 . More news on: Jounce Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- New data from vopratelimab and JTX-8064 presented at AACR 2019 - - On track to initiate new Phase 2 studies of vopratelimab - - Ended the quarter with $173.2 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET...
CAMBRIDGE, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report first quarter 2019 financial results ...
News, Short Squeeze, Breakout and More Instantly...
Jounce Therapeutics Inc. Company Name:
JNCE Stock Symbol:
NASDAQ Market:
Jounce Therapeutics Inc. Website:
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Co...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or t...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE)...